Chronic Obstructive Pulmonary Disease (COPD) is usually done at rest by spirometry test. But cardiopulmonary exercise test (CPET) can be a measure to assess the functional capacity more accurately in patients with COPD.
Ingenious Health Care, Ring Road, Shyamoli, Dhaka, Bangladesh Background and Aims: Assessment of severity in patients with Chronic Obstructive Pulmonary Disease (COPD) is usually done at rest by spirometry test. But cardiopulmonary exercise test (CPET) can be a measure to assess the functional capacity more accurately in patients with COPD.
Methods: Fifty eight patients with stable COPD were included in this study and categorised into four groups based on spirometric data following the GOLD guidelines 2018; GOLD 1 : mild COPD, GOLD 2: moderate COPD, GOLD 3: severe COPD and GOLD 4: very severe COPD. Symptom limited CPET was performed on treadmill using Bruce protocol through cardiopulmonary exercise machine in all fifty eight patients.
Results: Twenty one patients (36.20%) had moderate COPD; twenty six (44.82%) had severe COPD; eleven (18.96%) had very severe COPD and none were found to be categorised as mild COPD. All fifty eight patients attained anaerobic threshold (AT). Majority (34, 58.62%) of patients stopped exercise due to shortness of breath; decreased oxygen saturation was the cause of stopping exercise in eight (13.7%) patients; other causes of exercise limitation were increased heart rate , vertigo, leg fatigue, increased blood pressure, ventricular ectopic and chest tightness. Four patients were found to limit exercise due to combined shortness of breath and leg fatigue.
A significant correlation (r = 0.47, P = 0.001) between forced expiratory volume in first second (FEV 1, % predicted) and maximum oxygen uptake (Vo 2 max, mL/kg/min) was observed. Twenty seven (46.55%) patients with low (<40%) AT were identified among them seven were in GOLD 2 stage, twelve were in GOLD 3 stage and eight were in GOLD 4 stage.
Conclusion:
Cardiopulmonary Exercise Test is useful to measure the functional capacity in COPD patients by assessing the maximum oxygen uptake. Thus it could be a good monitoring tool to see the outcome of pulmonary rehabilitation program for COPD patients. Background and Aims: The differential diagnosis in patients with persistent airway limitation is sometimes not clear in older adults. Eosinophil inflammation in the airways may be observed in some cases with COPD, independent of asthma. However, little is known about airway eosinophilia in COPD in detail. This retrospective clinical study was designed to examine how airway eosinophilia develops in patients with COPD who have no symptom and no past history of asthma, and to determine whether addition to inhaled glucocorticosteroid (ICS) on these cases is beneficial.
Methods: Sputum examination was carried out in the stable COPD (GOLD 2-3) with daily inhalation of long-acting bronchodilators (LABAs and LAMAs). When airway eosinophilia was diagnosed by qualitative (+) or quantitative assessment (>2%), ICS was added on these patients.
COPD assessment test (CAT) and lung function test were followed up. In cases with FEV 1 >1.7 L or >70% of predicted values, acethylcholine provocation test was examined for assessment of airway hyperresponsiveness (AHR).
Results: Eosinophils in sputum were observed in 48 (43.2%) of 111 cases who have no clinical features of asthma. In 12 cases (48.0%) of 25 cases, the value of PC20 in the provocative test was less than 8000 mg/mL. After administration of ICS, CAT score were decreased from 8.8 to 5.1 points, and FEV1 and IC were further increased by 151.0 and 239.6 mL, respectively (each P < 0.05). During observation for one year, exacerbation did not occur, in contrast dyspnea and wheezing occurred in four cases among patients who did not administrate ICS because of sputum eosinophil less than 2%.
Conclusion: Airway eosinophilia and AHR, which are characteristic features of asthma, develop in approximate 45% of COPD independent of asthma. Addition of ICS to bronchodilators is very effective on COPD with airway eosinophilia, which may be a novel phenotype of COPD, different from asthma-COPD overlap. 
Methods:
We selected COPD patients for long-term follow-up since on June 2016. The subjects were required to fill out the related journal of the disease and wear a specific intelligent wristbands to recorded the daily activities and sleeping. To explore the change of the daily activities and night sleeping within the first 2 weeks, the acute exacerbation, and the 2 weeks after the acute exacerbation. cant difference between the step number and the mileage of the acute exacerbation 2 weeks before the acute exacerbation and the 2 weeks after the acute exacerbation (P = 0.002-0.012). Compared the reduction to the step number and mileage within before acute exacerbation and on
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